First Trust Nasdaq Pharmaceuticals ETF
FTXH
19 hedge funds and large institutions have $8.13M invested in First Trust Nasdaq Pharmaceuticals ETF in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 7 closing their positions.
8% less capital invested
Capital invested by funds: $8.87M → $8.13M (-$737K)
8.79% less ownership
Funds ownership: 47.56% → 38.77% (-8.8%)
14% less funds holding
Funds holding: 22 → 19 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$1.01M |
| 2 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$253K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$245K |
| 4 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
+$235K |
| 5 |
CA
Continuum Advisory
Eagle,
Idaho
|
+$17.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenview Trust
Louisville,
Kentucky
|
-$615K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$493K |
| 3 |
Goldman Sachs
New York
|
-$485K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$378K |
| 5 |
OWA
Outlook Wealth Advisors
Shenandoah,
Texas
|
-$229K |
FTXH Hedge Fund Activity: Q1 2024 in Review
19 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2024, worth a combined $8.13M — down 8.3% from $8.87M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FTXH and 4 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was Janney Montgomery Scott, opening a new position worth an estimated $1.01M. The largest seller was Glenview Trust, exiting entirely with an estimated $615K sold.
- 19 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2024, down from 22 in Q4 2023.
- Funds reported $8.13M of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2024, down 8.3% quarter-over-quarter.
- 4 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2024 and 7 closed out, a net change of -3 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2024 was Janney Montgomery Scott, an estimated $1.01M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2024 was Glenview Trust, an estimated $615K sold.
Based on aggregated 13F filings for Q1 2024.